JAKAFI (ruxolitinib phosphate)
ANTINEOPLASTIC - JANUS KINASE (JAK) INHIBITORS·POLYCYTHEMIA VERA·+3
Incyte Corporation
Indication
Chronic graft-versus-host disease
Chronic graft-versus-host disease is a serious, multi-organ alloimmune and autoimmune-like complication that occurs following allogeneic hematopoietic cell transplantation. Read more about Chronic graft-versus-host disease
6 drugs 3 manufacturers
Drugs that treat it
Common Chronic graft-versus-host disease therapies.
IMBRUVICA (ibrutinib)
ANTINEOPLASTIC - PROTEIN-TYROSINE KINASE INHIBITORS·CHRONIC LYMPHOCYTIC LEUKEMIA·+5
PHARMACYCLICS,
IMBRUVICA (ibrutinib)
ANTINEOPLASTIC - PROTEIN-TYROSINE KINASE INHIBITORS·CHRONIC LYMPHOCYTIC LEUKEMIA·+5
PHARMACYCLICS,
REZUROCK (belumosudil mesylate)
IMMUNOMODULATOR - RHO KINASE INHIBITOR·CHRONIC GRAFT-VERSUS-HOST DISEASE
KADMON/SANOFI-A
NIKTIMVO (axatilimab-csfr)
IMMUNOSUPPRESS., T-CELL FXN INHIBITING MONOCLONAL ANTIBODIES·CHRONIC GRAFT-VERSUS-HOST DISEASE
Incyte Corporation
JAKAFI XR (ruxolitinib phosphate)
ANTINEOPLASTIC - JANUS KINASE (JAK) INHIBITORS·POLYCYTHEMIA VERA·+3
Incyte Corporation
Filter & compare in the drug finder →Opens the drug finder with Chronic graft-versus-host disease preselected.
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonChronic graft-versus-host disease is a serious, multi-organ alloimmune and autoimmune-like complication that occurs following allogeneic hematopoietic cell transplantation.
The disease arises when donor-derived immunocompetent T and B cells recognize recipient tissues as foreign, initiating dysregulated immune responses, persistent inflammation, and progressive tissue fibrosis.
It frequently involves the skin, oral mucosa, eyes, liver, gastrointestinal tract, musculoskeletal system, and lungs, leading to clinical manifestations such as sclerotic or lichenoid changes, keratoconjunctivitis sicca, joint contractures, and bronchiolitis obliterans.
Chronic graft-versus-host disease remains a leading cause of late non-relapse morbidity and mortality in post-transplant populations.
- nih.gov
Chronic graft-versus-host disease is a serious, multi-organ alloimmune and autoimmune-like complication that occurs following allogeneic hematopoietic cell transplantation
- nih.gov
Chronic graft-versus-host disease is a serious, multi-organ alloimmune and autoimmune-like complication that occurs following allogeneic hematopoietic cell transplantation The disease arises when donor-derived immunocompetent T and B cells recognize recipient tissues as foreign, initiating dysregulated immune responses, persistent inflammation, and progressive tissue fibrosis Chronic graft-versus-host disease remains a leading cause of late non-relapse morbidity and mortality in post-transplant ...
- nih.gov
The disease arises when donor-derived immunocompetent T and B cells recognize recipient tissues as foreign, initiating dysregulated immune responses, persistent inflammation, and progressive tissue fibrosis
- cancer.gov
The disease arises when donor-derived immunocompetent T and B cells recognize recipient tissues as foreign, initiating dysregulated immune responses, persistent inflammation, and progressive tissue fibrosis It frequently involves the skin, oral mucosa, eyes, liver, gastrointestinal tract, musculoskeletal system, and lungs, leading to clinical manifestations such as sclerotic or lichenoid changes, keratoconjunctivitis sicca, joint contractures, and bronchiolitis obliterans
- cancer.gov
It frequently involves the skin, oral mucosa, eyes, liver, gastrointestinal tract, musculoskeletal system, and lungs, leading to clinical manifestations such as sclerotic or lichenoid changes, keratoconjunctivitis sicca, joint contractures, and bronchiolitis obliterans
- dana-farber.org
It frequently involves the skin, oral mucosa, eyes, liver, gastrointestinal tract, musculoskeletal system, and lungs, leading to clinical manifestations such as sclerotic or lichenoid changes, keratoconjunctivitis sicca, joint contractures, and bronchiolitis obliterans
- ashpublications.org
Chronic graft-versus-host disease remains a leading cause of late non-relapse morbidity and mortality in post-transplant populations
Personalize your experience
Follow Chronic graft-versus-host disease and get updates as they land.
Create a free account
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.